BioLargo (BLGO) Q4 2025 earnings summary

Executive summary

• Transitioned from development to commercialization across four validated technology platforms in 2025, focusing on growth and value creation.

• Achieved key milestones: municipal installation of AEC water treatment, commercial launch of Clyra Medical, and third-party validation of Cellinity Battery technology; engineering services revenue doubled year-over-year.

• Managed Pooph license breach with legal action and repositioned ONM Environmental for new partnerships.

• Diversified business model with ownership stakes (49%-100%) in subsidiaries and a 6% royalty on sales, supporting consistent revenue.

• Raised $5.75M for Clyra Medical in 2025 and $1.7M post-year-end to support commercial scaling.

Financial highlights

• 2025 revenue declined to $7.77 million, primarily due to termination of the Pooph licensing agreement.

• Net loss for 2025 was $15.19 million; stockholders' equity decreased to $1.53 million.

• Maintained strong liquidity with $3.88 million in cash at year-end, avoiding toxic debt.

• Service/engineering revenue doubled year-over-year to $2 million, indicating organic growth in core business.

• Booked a $3.85 million credit loss related to Pooph, compounding revenue decline.

Outlook and guidance

• Anticipates multiple catalysts in 2026, including national rollout of Clyra Medical, expanded AEC validation, and first Cellinity Battery joint venture contract.

• Expects ONM Environmental to announce new partnerships and expand IP/product designs.

• Sees substantial valuation gap versus portfolio potential, with strong industry tailwinds in PFAS regulation, energy storage, and infection control.